Differential effects of low- and high-dose GW2974, a dual epidermal growth factor receptor and HER2 kinase inhibitor, on glioblastoma multiforme invasion

Journal of Neuroscience Research

Volumn 91, Issue 1, 2013, Pages 128-137

  Wang, Lulu ^a,b   Liu, Qian ^a   Zhao, Hong ^b   Cui, Kemi ^b   Yao, Linli ^a   Nie, Fang ^b   Jin, Guangxu ^b   Hao, Aijun ^a   Wong, Stephen T C ^b  

^a SHANDONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

EGFR; Glioblastoma; GW2974; Invasion; P38 MAPK

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GW 2974; MITOGEN ACTIVATED PROTEIN KINASE P38; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; DRUG MEGADOSE; DRUG TARGETING; GLIOBLASTOMA; HUMAN; HUMAN CELL; LOW DRUG DOSE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN MICROARRAY; TUMOR GROWTH; TUMOR XENOGRAFT; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; BRAIN NEOPLASMS; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; GLIOBLASTOMA; HUMANS; MALE; MICE; MICE, SCID; NEOPLASM INVASIVENESS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROTEIN ARRAY ANALYSIS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84869208017     PISSN: 03604012     EISSN: 10974547     Source Type: Journal    
DOI: 10.1002/jnr.23140     Document Type: Article

References (55)

1. Andersson U, Guo D, Malmer B, Bergenheim AT, Brannstrom T, Hedman H, Henriksson R. 2004. Epidermal growth factor receptor family (EGFR, ErbB2-4) in gliomas and meningiomas. Acta Neuropathol 108: 135-142.
2. Angelucci A. 2009. Targeting ERBB receptors to inhibit metastasis: old hopes and new certainties. Curr Cancer Drug Targets 9: 1-18.
3. Bello L, Giussani C, Carrabba G, Pluderi M, Lucini V, Pannacci M, Caronzolo D, Tomei G, Villani R, Scaglione F, Carroll RS, Bikfalvi A. 2002. Suppression of malignant glioma recurrence in a newly developed animal model by endogenous inhibitors. Clin Cancer Res 8: 3539-3548.
4. Bhatt AJ, Pryhuber GS, Huyck H, Watkins RH, Metlay LA, Maniscalco WM. 2001. Disrupted pulmonary vasculature and decreased vascular endothelial growth factor, Flt-1, and TIE-2 in human infants dying with bronchopulmonary dysplasia. Am J Respir Crit Care Med 164: 1971-1980.
5. Brown PD, Krishnan S, Sarkaria JN, Wu W, Jaeckle KA, Uhm JH, Geoffroy FJ, Arusell R, Kitange G, Jenkins RB, Kugler JW, Morton RF, Rowland KMJr, Mischel P, Yong WH, Scheithauer BW, Schiff D, Giannini C, Buckner JC. 2008. Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177. J Clin Oncol 26: 5603-5609.
6. Bublil EM, Yarden Y. 2007. The EGF receptor family: spearheading a merger of signaling and therapeutics. Curr Opin Cell Biol 19: 124-134.
7. Cockerill S, Stubberfield C, Stables J, Carter M, Guntrip S, Smith K, McKeown S, Shaw R, Topley P, Thomsen L, Affleck K, Jowett A, Hayes D, Willson M, Woollard P, Spalding D. 2001. Indazolylamino quinazolines and pyridopyrimidines as inhibitors of the EGFr and C-erbB-2. Bioorg Med Chem Lett 11: 1401-1405.
8. Cuenda A, Rouse J, Doza YN, Meier R, Cohen P, Gallagher TF, Young PR, Lee JC. 1995. SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin-1. FEBS Lett 364: 229-233.
9. Drappatz J, Norden AD, Wen PY. 2009. Therapeutic strategies for inhibiting invasion in glioblastoma. Expert Rev Neurother 9: 519-534.
10. Duxbury MS, Ito H, Zinner MJ, Ashley SW, Whang EE. 2004. EphA2: a determinant of malignant cellular behavior and a potential therapeutic target in pancreatic adenocarcinoma. Oncogene 23: 1448-1456.
11. Ferrer-Soler L, Vazquez-Martin A, Brunet J, Menendez JA, De Llorens R, Colomer R. 2007. An update of the mechanisms of resistance to EGFR-tyrosine kinase inhibitors in breast cancer: gefitinib (Iressa)-induced changes in the expression and nucleo-cytoplasmic trafficking of HER-ligands (review). Int J Mol Med 20: 3-10.
12. Fischer I, Cunliffe CH, Bollo RJ, Raza S, Monoky D, Chiriboga L, Parker EC, Golfinos JG, Kelly PJ, Knopp EA, Gruber ML, Zagzag D, Narayana A. 2008. High-grade glioma before and after treatment with radiation and Avastin: initial observations. Neurooncol 10: 700-708.
13. Gabelloni P, Da Pozzo E, Bendinelli S, Costa B, Nuti E, Casalini F, Orlandini E, Da Settimo F, Rossello A, Martini C. 2010. Inhibition of metalloproteinases derived from tumours: new insights in the treatment of human glioblastoma. Neuroscience 168: 514-522.
14. Giese A, Bjerkvig R, Berens ME, Westphal M. 2003. Cost of migration: invasion of malignant gliomas and implications for treatment. J Clin Oncol 21: 1624-1636.
15. Gimenez-Cassina A, Lim F, Diaz-Nido J. 2006. Differentiation of a human neuroblastoma into neuron-like cells increases their susceptibility to transduction by herpesviral vectors. J Neurosci Res 84: 755-767.
16. Gunal A, Onguru O, Safali M, Beyzadeoglu M. 2008. Fascin expression in glial tumors and its prognostic significance in glioblastomas. Neuropathology 28: 382-386.
17. Hayashi Y, Yamashita J, Watanabe T. 2004. Molecular genetic analysis of deep-seated glioblastomas. Cancer Genet Cytogenet 153: 64-68.
18. He F, Sun YE. 2007. Glial cells more than support cells? Int J Biochem Cell Biol 39: 661-665.
19. Hedges JC, Dechert MA, Yamboliev IA, Martin JL, Hickey E, Weber LA, Gerthoffer WT. 1999. A role for p38(MAPK)/HSP27 pathway in smooth muscle cell migration. J Biol Chem 274: 24211-24219.
20. Herbst RS. 2004. Review of epidermal growth factor receptor biology. Int J Radiat Oncol Biol Phys 59(Suppl 2): 21-26.
21. Hwang JH, Smith CA, Salhia B, Rutka JT. 2008. The role of fascin in the migration and invasiveness of malignant glioma cells. Neoplasia 10: 149-159.
22. Kajita T, Ohta Y, Kimura K, Tamura M, Tanaka Y, Tsunezuka Y, Oda M, Sasaki T, Watanabe G. 2001. The expression of vascular endothelial growth factor C and its receptors in non-small cell lung cancer. Br J Cancer 85: 255-260.
23. Kastan MB. 1999. Molecular determinants of sensitivity to antitumor agents. Biochim Biophys Acta 1424: R37-R42.
24. Kiguchi K, Ruffino L, Kawamoto T, Ajiki T, Digiovanni J. 2005. Chemopreventive and therapeutic efficacy of orally active tyrosine kinase inhibitors in a transgenic mouse model of gallbladder carcinoma. Clin Cancer Res 11: 5572-5580.
25. Kishi Y, Okudaira S, Tanaka M, Hama K, Shida D, Kitayama J, Yamori T, Aoki J, Fujimaki T, Arai H. 2006. Autotaxin is overexpressed in glioblastoma multiforme and contributes to cell motility of glioblastoma by converting lysophosphatidylcholine to lysophosphatidic acid. J Biol Chem 281: 17492-17500.
26. Klauber N, Parangi S, Flynn E, Hamel E, D'Amato RJ. 1997. Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol. Cancer Res 57: 81-86.
27. Klement G, Baruchel S, Rak J, Man S, Clark K, Hicklin DJ, Bohlen P, Kerbel RS. 2000. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 105: R15-R24.
28. Kreisl TN, Lassman AB, Mischel PS, Rosen N, Scher HI, Teruya-Feldstein J, Shaffer D, Lis E, Abrey LE. 2009. A pilot study of everolimus and gefitinib in the treatment of recurrent glioblastoma (GBM). J Neurooncol 92: 99-105.
29. Lackey KE. 2006. Lessons from the drug discovery of lapatinib, a dual ErbB1/2 tyrosine kinase inhibitor. Curr Top Med Chem 6: 435-460.
30. Lal S, La Du J, Tanguay RL, Greenwood JA. 2012. Calpain 2 is required for the invasion of glioblastoma cells in the zebrafish brain microenvironment. J Neurosci Res 90: 769-781.
31. LeBlanc R, Catley LP, Hideshima T, Lentzsch S, Mitsiades CS, Mitsiades N, Neuberg D, Goloubeva O, Pien CS, Adams J, Gupta D, Richardson PG, Munshi NC, Anderson KC. 2002. Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res 62: 4996-5000.
32. Lee JC, Laydon JT, McDonnell PC, Gallagher TF, Kumar S, Green D, McNulty D, Blumenthal MJ, Heys JR, Landvatter SW, et al. 1994. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 372: 739-746.
33. Lefranc F, Brotchi J, Kiss R. 2005. Possible future issues in the treatment of glioblastomas: special emphasis on cell migration and the resistance of migrating glioblastoma cells to apoptosis. J Clin Oncol 23: 2411-2422.
34. Lind CR, Gray CW, Pearson AG, Cameron RE, O'Carroll SJ, Narayan PJ, Lim J, Dragunow M. 2006. The mitogen-activated/extracellular signal-regulated kinase kinase 1/2 inhibitor U0126 induces glial fibrillary acidic protein expression and reduces the proliferation and migration of C6 glioma cells. Neuroscience 141: 1925-1933.
35. Ma Y, Wang B, Li W, Liu X, Wang J, Ding T, Zhang J, Ying G, Fu L, Gu F. 2011. Intersectin1-s is involved in migration and invasion of human glioma cells. J Neurosci Res 89: 1079-1090.
36. Mariani L, Beaudry C, McDonough WS, Hoelzinger DB, Demuth T, Ross KR, Berens T, Coons SW, Watts G, Trent JM, Wei JS, Giese A, Berens ME. 2001. Glioma cell motility is associated with reduced transcription of proapoptotic and proliferation genes: a cDNA microarray analysis. J Neurooncol 53: 161-176.
37. Montemurro F, Valabrega G, Aglietta M. 2007. Lapatinib: a dual inhibitor of EGFR and HER2 tyrosine kinase activity. Expert Opin Biol Ther 7: 257-268.
38. Morgillo F, Cantile F, Fasano M, Troiani T, Martinelli E, Ciardiello F. 2009. Resistance mechanisms of tumour cells to EGFR inhibitors. Clin Transl Oncol 11: 270-275.
39. Nelson MH, Dolder CR. 2006. Lapatinib: a novel dual tyrosine kinase inhibitor with activity in solid tumors. Ann Pharmacother 40: 261-269.
40. Rubin JB, Kung AL, Klein RS, Chan JA, Sun Y, Schmidt K, Kieran MW, Luster AD, Segal RA. 2003. A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors. Proc Natl Acad Sci U S A 100: 13513-13518.
41. Rusnak DW, Affleck K, Cockerill SG, Stubberfield C, Harris R, Page M, Smith KJ, Guntrip SB, Carter MC, Shaw RJ, Jowett A, Stables J, Topley P, Wood ER, Brignola PS, Kadwell SH, Reep BR, Mullin RJ, Alligood KJ, Keith BR, Crosby RM, Murray DM, Knight WB, Gilmer TM, Lackey K. 2001. The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer. Cancer Res 61: 7196-7203.
42. Sharma GD, He J, Bazan HE. 2003. P38 and ERK1/2 coordinate cellular migration and proliferation in epithelial wound healing: evidence of cross-talk activation between MAP kinase cascades. J Biol Chem 278: 21989-21997.
43. Smith L, Watson MB, O'Kane SL, Drew PJ, Lind MJ, Cawkwell L. 2006. The analysis of doxorubicin resistance in human breast cancer cells using antibody microarrays. Mol Cancer Ther 5: 2115-2120.
44. Spector NL, Yarden Y, Smith B, Lyass L, Trusk P, Pry K, Hill JE, Xia W, Seger R, Bacus SS. 2007. Activation of AMP-activated protein kinase by human EGF receptor 2/EGF receptor tyrosine kinase inhibitor protects cardiac cells. Proc Natl Acad Sci U S A 104: 10607-10612.
45. Sun Z, Sood S, Li N, Yang P, Newman RA, Yang CS, Chen X. 2008. Chemoprevention of 7, 12-dimethylbenz[a]anthracene (DMBA)-induced oral carcinogenesis in hamster cheek pouch by topical application of a dual inhibitor of epidermal growth factor receptor (EGFR) and ErbB2 tyrosine kinases. Oral Oncol 44: 652-657.
46. Szentirmai O, Baker CH, Lin N, Szucs S, Takahashi M, Kiryu S, Kung AL, Mulligan RC, Carter BS. 2006. Noninvasive bioluminescence imaging of luciferase expressing intracranial U87 xenografts: correlation with magnetic resonance imaging determined tumor volume and longitudinal use in assessing tumor growth and antiangiogenic treatment effect. Neurosurgery 58: 365-372.
47. Thiessen B, Stewart C, Tsao M, Kamel-Reid S, Schaiquevich P, Mason W, Easaw J, Belanger K, Forsyth P, McIntosh L, Eisenhauer E. 2009. A phase I/II trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: clinical outcomes, pharmacokinetics and molecular correlation. Cancer Chemother Pharmacol 65: 353-361.
48. Voelzke WR, Petty WJ, Lesser GJ. 2008. Targeting the epidermal growth factor receptor in high-grade astrocytomas. Curr Treat Options Oncol 9: 23-31.
49. Wechsler-Reya R, Scott MP. 2001. The developmental biology of brain tumors. Annu Rev Neurosci 24: 385-428.
50. Weidner N, Carroll PR, Flax J, Blumenfeld W, Folkman J. 1993. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 143: 401-409.
51. Wen PY, Kesari S. 2008. Malignant gliomas in adults. N Engl J Med 359: 492-507.
52. Yarden Y. 2001. The EGFR family and its ligands in human cancer. Signalling mechanisms and therapeutic opportunities. Eur J Cancer 37(Suppl 4): S3-S8.
53. Yoshida H, Fujita S, Nishida M, Iizuka T. 1999. Angiogenesis in the human temporomandibular joint studied by immunohistochemistry for CD34 antigen. J Oral Pathol Med 28: 289-292.
54. Zhang H, Berezov A, Wang Q, Zhang G, Drebin J, Murali R, Greene MI. 2007. ErbB receptors: from oncogenes to targeted cancer therapies. J Clin Invest 117: 2051-2058.
55. Zhao H, Tang C, Cui K, Ang BT, Wong ST. 2009. A screening platform for glioma growth and invasion using bioluminescence imaging. Laboratory investigation. J Neurosurg 111: 238-246.